Planning, Reporting, and Selective Disclosure of Quality-of-Life End Points in Phase III Genitourinary Cancer Trials
JCO Oncology Advances · 2026-07 · 3 (3)
DOI: 10.1200/oa-26-00044 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Advances, 2026-07. Verfasst von Shreyas Kalantri und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology/Hematology, Brown Cancer Center, University of Louisville, Louisville, KY. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.
Abstract (Originalsprache)
PURPOSE Quality-of-life (QoL) end points are essential for treatment decisions and value assessment in genitourinary (GU) cancer, yet the extent of QoL planning-reporting concordance and outcome reporting bias is unknown. We evaluated the frequency, correlates, and concordance of QoL end point planning and reporting in phase III GU cancer trials. METHODS We conducted a systematic review of phase III randomized clinical trials evaluating systemic therapies for GU malignancies published from 2020 through 2024 (PubMed, EMBASE). QoL prespecification was ascertained from ClinicalTrials.gov or protocols. Associations with QoL reporting were assessed using univariable and multivariable logistic regression. RESULTS Among 80 clinical trials, QoL was prespecified in 68 (85%) yet reported in only 38 (47.5%). Of the 68 trials that prespecified QoL, 30 (44.1%) did not report results. Positive primary end point results were the strongest correlate of QoL reporting (63% v 25%; adjusted odds ratio [OR], 4.84 [95% CI, 1.74 to 14.60]; P = .003). Single-country scope was independently associated with lower QoL reporting (OR, 0.22 [95% CI, 0.04 to 0.83]; P = .04). Among trials that prespecified QoL, the association with result direction persisted (71% v 31%; P = .001), and neither funding source nor journal impact factor explained the discrepancy. QoL reporting rates were similar from 2020 through 2023 (50%-61%) and dropped to 11% in 2024; in a sensitivity analysis modeling publication year categorically, only 2024 differed significantly from 2020 (OR, 0.07 [95% CI, 0.01 to 0.34]; P = .003). No trial designated QoL as a primary end point. CONCLUSION QoL end points in GU cancer trials are frequently planned but selectively reported, with findings consistent with result-dependent disclosure. This pattern may compromise value assessment frameworks and shared decision making. Enforcement of CONSORT-PRO, SPIRIT-PRO, and SISAQOL standards is needed.
Autor:innen und Institutionen
- Division of Medical Oncology/Hematology, Brown Cancer Center, University of Louisville, Louisville, KY.
- Department of Medicine, University of Louisville, Louisville, KY.
- Department of Public Health Sciences, University of Chicago, Chicago, IL.
- Cancer Prevention and Control Research Program, UChicago Medicine Comprehensive Cancer Center, Chicago, IL.
- Center for Health and the Social Sciences, University of Chicago, Chicago, IL.
- School of Medicine, University of Louisville, Louisville, KY.
ORCID-Profile: Shreyas Kalantri, Shiva Balasubramanian, Jincong Q Freeman, Tyler Jones, Priyanka Sheth, Jason Chesney, Rohit Kumar
Förderung
- NIA NIH HHS
Zitieren
APA
Kalantri, S., Balasubramanian, S., Freeman, J. Q., Jones, T., Sheth, P., Karthik, S., Chesney, J., & Kumar, R. (2026). Planning, Reporting, and Selective Disclosure of Quality-of-Life End Points in Phase III Genitourinary Cancer Trials. JCO Oncology Advances, 3(3). https://doi.org/10.1200/oa-26-00044
Vancouver
Kalantri S, Balasubramanian S, Freeman JQ, Jones T, Sheth P, Karthik S, et al. Planning, Reporting, and Selective Disclosure of Quality-of-Life End Points in Phase III Genitourinary Cancer Trials. JCO Oncology Advances. 2026;3(3). doi:10.1200/oa-26-00044
BibTeX
@article{Kalantri2026,
author = {Kalantri, Shreyas and Balasubramanian, Shiva and Freeman, Jincong Q and Jones, Tyler and Sheth, Priyanka and Karthik, Srinidhi and Chesney, Jason and Kumar, Rohit},
title = {Planning, Reporting, and Selective Disclosure of Quality-of-Life End Points in Phase III Genitourinary Cancer Trials},
journal = {JCO Oncology Advances},
year = {2026},
volume = {3},
number = {3},
doi = {10.1200/oa-26-00044}
}
EUVIMED